# MacroGenics Doses First Patient in Phase 1 Trial of Cancer Drug MGC030

- URL: https://stocks.freetheai.org/news/macrogenics-doses-first-patient-in-phase-1-trial-of-cancer-drug-mgc030-9a6097
- Published: 2026-10-15T20:05:00Z
- Category: company_news; sentiment: bullish; impact: low
- Symbols: [NASDAQ:MGNX](https://stocks.freetheai.org/symbols/NASDAQ-MGNX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

MacroGenics, Inc. (MGNX) has administered the initial dose to the first patient in an open-label Phase 1 clinical trial evaluating MGC030, an experimental treatment for advanced solid tumors. MGC030 is a first-in-class antibody-drug conjugate designed to target an undisclosed antigen for which no approved treatments currently exist. The dose-escalation portion of the study is expected to enroll up to 54 participants.

The initiation of this study marks the third antibody-drug conjugate candidate entering active clinical development for MacroGenics. The drug utilizes the Synaffix SYNtecan E payload, which belongs to the topoisomerase I payload class. Advancing a novel therapy against an unvalidated target offers potential pipeline growth for the company as it expands its focus on antibody-drug conjugate technologies. Shares of MacroGenics rose 1.96% to $3.375 following the announcement.

Investors and clinical observers will monitor the trial as it progresses through dose escalation and expansion cohorts. Key near-term catalysts for the program include initial readouts on safety, pharmacokinetics, and any early signals of antitumor activity in treated patients.

## Key points

- MacroGenics, Inc. (MGNX) dosed the first patient in a Phase 1 trial for its experimental cancer treatment, MGC030.
- The open-label study will include dose escalation and plans to enroll up to 54 participants with advanced solid tumors.
- MGC030 is a first-in-class antibody-drug conjugate targeting an undisclosed antigen using a Synaffix SYNtecan E payload.
- The trial represents the third antibody-drug conjugate candidate that MacroGenics has moved into active clinical development.
- Future study milestones will focus on evaluating the drug's safety, pharmacokinetics, and initial antitumor response.

## Questions and answers

### What is MGC030 and what condition does it target?

MGC030 is a first-in-class antibody-drug conjugate developed by MacroGenics, Inc. to treat patients with advanced solid tumors. It utilizes a Synaffix SYNtecan E payload and targets an undisclosed antigen with no existing approved therapies.

### How many patients will participate in the Phase 1 trial of MGC030?

The Phase 1 open-label study includes a dose-escalation design that is expected to enroll up to 54 participants.

### What are the key upcoming catalysts for the MGC030 study?

Key future milestones include readouts on initial safety, pharmacokinetics, and early signs of antitumor efficacy from the study's dose-escalation and expansion cohorts.